Brought to you by 
Series B raises $30mm for antibody company CytomX; later adds $11mm
18 Jun 2015
Executive Summary
First-time investors Third Rock Ventures (lead) and the Roche Venture Fund have joined together in a $30mm Series B1 preferred stock financing for next-generation antibody developer CytomX Therapeutics LLC. Two members from Third Rock have been nominated to the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B raises $30mm for antibody company CytomX; later adds $11mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice